The Indian clinical research organisation SIRO Clinpharm has appointed Dr Vatsal Shah as the head of its US operations, which is designed to support trials from Phase II to Phase IV and beyond post-launch of products. Dr. Shah will be located at their New Jersey headquarters.
The appointment follows the recent restructure of Siro Clinpharm’s core brand elements to reflect its growth and establish a strong operational presence in the US. Dr Shah is currently the COO of Siro Clinpharm and will transition into the global chief operating officer’s (COO) role to lead this expansion.
“SIRO is uniquely poised to grow quickly based on the high trust and respect it enjoys amongst global clients. The US market is strategically important for us. We will continue to invest there and expand quickly.”stated Dr Shah in a statement on Tuesday (11 June).